We Want Antibiotics

* A blog of Indian Initiative for Management of Antibiotic Resistance (IIMAR) managed by Dr. A. J. Tamhankar

Friday, May 7, 2010

Global scenario of microbes, infections, antibiotics and resistance - By Dr. A.J. Tamhankar

-How A Novel Class Of Antibodies Inhibits HIV Infection
-Cubist Pharmaceuticals Enrolls 1st Subject In Phase 2 Trial For Therapy To Treat Clostridium -Difficile-Associated Diarrhea, Or CDAD
-FDA Provides Information To Consumers About The Ingredient Triclosan-New Model Tracks The Immune Response To A T
-Cempra Announces Expansion Of Clinical Management Team To Advance Leading Antibacterial Clinical Programs TAKSTA(TM) And CEM-101-Optimer Pharmaceuticals Announces Presentations Of Data From The Fidaxomicin Phase 3 Trials At ECCMID-Pathogenic Fungus Loves Brain Sugar
Dr. A. J. Tamhankar, National Coordinator for Indian Initiative for Management of Antibiotic Resistance (IIMAR) at 7:40 AM

No comments:

Post a Comment

‹
›
Home
View web version

Contributors

  • Dr. A. J. Tamhankar, National Coordinator for Indian Initiative for Management of Antibiotic Resistance (IIMAR)
  • Dr. Akilesh Ramasamy
Powered by Blogger.